Table 1.
Gene | Primer sequences |
---|---|
UGT genes | |
UGT1A5 | Sense: 5′-CAACGGGAAGCCACTATCTCAGG-3′ |
Antisense: 5′-CCACAATTCCATGTTCTCCAGAAGC-3′ | |
UGT2A1 | Sense: 5′-CATTGCTCACATGAAGGCCAAAGG-3′ |
Antisense: 5′-GCGCTAAGCAAATCCACACTTGTC-3′ | |
UGT2B4 | Sense: 5′-CCACTGCAAACCTGCCAAACC-3′ |
Antisense: 5′-TCTTCTGACGTGTTACTGACCATCG-3′ | |
UGT2B7 | Sense: 5′-TTGCCGATCAACCTGATAACATTGC-3′ |
Antisense: 5′-AGCAAGTCTGTACTCGACATTGTG-3′ | |
UGT2B15 | Sense: 5′-GGAAATGGAAGAGTTTGTGCAGAGC-3′ |
Antisense: 5′-GGATCTGGGCAAGGGCTGATG-3′ | |
UGT2B11 | Sense: 5′-TGCTTGTCATAAGGCAGACATCATC-3′ |
Antisense: 5′-TGAGGTGACTGTACTGGCATCTTC-3′ | |
Cancer progression-associated genes | |
CCNA2 | Sense: 5′-AACAGCCAGACATCACTAACAG-3′ |
Antisense: 5′-CTCAGCACTGACATGGAAGAC-3′ | |
CDKN3 | Sense: 5′-GAGGGACTCCTGACATAGCC-3′ |
Antisense: 5′-AGACAAGCAGCTACAAGACAAG-3′ | |
ESCO2 | Sense: 5′-TCAGACTGAAGAGAAGAAAGCG-3′ |
Antisense: 5′-TGGTGTTGGGTCAGAAAATGC-3′ | |
EXT1 | Sense: 5′-AGGAGACAATGATGGGACAGAC-3′ |
Antisense: 5′-AGTGGATCAGCGGCATGTAG-3′ | |
LATS1 | Sense: 5′-GTGTGATTGGTGGAGTGTTGG-3′ |
Antisense: 5′-TGTGGTGGAATGTGAAGAGATG-3′ | |
PAFAH1B1 | Sense: 5′-TGCTGATGACAAGACCCTACG-3′ |
Antisense: 5′-TGATCTACGCTGCCAGTGAC-3′ | |
PLCB1 | Sense: 5′-GCTTAATCTTCGGCAAGAACAG-3′ |
Antisense: 5′-CTGACACTCTTCTGCGACATC-3′ | |
PRKCA | Sense: 5′-CCTATGGCGTCCTGTTGTATG-3′ |
Antisense: 5′-CAGATAGAAACAGCCTCCTTGG-3′ | |
Endogenous control | |
GAPDH | Sense: 5′-ACACCCACTCCTCCACCTTT-3′ |
Antisense: 5′-TAGCCAAATTCGTTGTCATACC-3′ |
CCNA2, cyclin A2; CDKN3, cyclin-dependent kinase inhibitor 3; LATS1, large tumour suppressor homologue 1; PRKCA, protein kinase C alpha; qPCR, quantitative real-time polymerase chain reaction; UGT, UDP glucuronosyltransferase.